Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765100 | 0.85 | — | — | |
| SCHEMBL20465742 | 0.85 | — | — | |
| SCHEMBL5054 | 0.85 | — | — | |
| SCHEMBL4441044 | 0.83 | TAAR1 (0.52) | IDO1TAAR1AOC3ALDH1A1L3MBTL1 | |
| SCHEMBL1538044 | 0.83 | TAAR1 (0.52) | IDO1TAAR1AOC3ALDH1A1L3MBTL1 | |
| Benzene SCHEMBL28870609 | 0.83 | TAAR1 (0.52) | IDO1TAAR1AOC3ALDH1A1KDM4E | |
| Water SCHEMBL450787 | 0.83 | TAAR1 (0.52) | IDO1TAAR1AOC3ALDH1A1L3MBTL1 | |
| SCHEMBL12874173 | 0.79 | IDO1 (0.57) | IDO1TAAR1AOC3ALDH1A1KDM4E | |
| Formic Acid Methyl Ester SCHEMBL28105659 | 0.77 | IDO1 (0.41) | IDO1TAAR1AOC3ALDH1A1L3MBTL1 | |
| Benzyl Bromide SCHEMBL6043969 | 0.75 | ALDH1A1 (0.61) | IDO1TAAR1AOC3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065219-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-03-15 | — | — | US | disclosed |
| US-8076350-B2 | 3H-(4's)-1'-azaspiro[benzofuran-2,4']-tricyclo[3.3.1.13,7]decane; for therapy of memory disorder, cognitive disorder, neurodegeneration, and neurodevelopmental disorder; attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment | ABBOTT LABORATORIES (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2253631-A1 | Spyrocyclic quiniclidinic ether derivatives | Abbott Laboratories (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2114943-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | Abbott Laboratories (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008079570-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| US-7045530-B2 | Spirocyclic quinuclidinic ether derivatives | ABBOTT LABORATORIES (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050137219-A1 | Spirocyclic quinuclidinic ether derivatives | ABBVIE INC. | 2005-06-23 | — | — | US | disclosed |
| US-20050137217-A1 | Spirocyclic quinuclidinic ether derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065219-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | IDO1 2822/4885TAAR1 361/4885AOC3 818/4885 |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | IDO1 2970/4885TAAR1 427/4885AOC3 949/4885 |
| US-20050137217-A1 | Spirocyclic quinuclidinic ether derivatives | CHRNA1, CHRNA7, CHRNA2 | IDO1 2896/4885TAAR1 247/4885AOC3 1921/4885 |
| US-20050137219-A1 | Spirocyclic quinuclidinic ether derivatives | CHRNA1, CHRNA7, CHRNA2 | IDO1 2896/4885TAAR1 247/4885AOC3 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.